EA202090581A1 - Продукты слияния транстиретина и иммуноглобулина - Google Patents

Продукты слияния транстиретина и иммуноглобулина

Info

Publication number
EA202090581A1
EA202090581A1 EA202090581A EA202090581A EA202090581A1 EA 202090581 A1 EA202090581 A1 EA 202090581A1 EA 202090581 A EA202090581 A EA 202090581A EA 202090581 A EA202090581 A EA 202090581A EA 202090581 A1 EA202090581 A1 EA 202090581A1
Authority
EA
Eurasian Patent Office
Prior art keywords
transtyretin
immunoglobulin
fusion products
ttr
antibodies
Prior art date
Application number
EA202090581A
Other languages
English (en)
Inventor
Кеннет Уолкер
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA202090581A1 publication Critical patent/EA202090581A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

Настоящее изобретение относится к продуктам слияния на основе транстиретина (TTR), пригодным для димеризации и тетрамеризации антител и фрагментов антител, таких как Fab. Описанные в данном документе белки слияния на основе TTR особенно пригодны для повышения авидности антител и для усиления кластеризации антигенов. Способы лечения заболеваний с применением слитых белков по настоящему изобретению описаны в данном документе.
EA202090581A 2017-10-04 2018-10-03 Продукты слияния транстиретина и иммуноглобулина EA202090581A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762568217P 2017-10-04 2017-10-04
PCT/US2018/054237 WO2019070901A1 (en) 2017-10-04 2018-10-03 IMMUNOGLOBULIN FUSIONS OF TRANSTHYRETIN

Publications (1)

Publication Number Publication Date
EA202090581A1 true EA202090581A1 (ru) 2020-08-31

Family

ID=64110020

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090581A EA202090581A1 (ru) 2017-10-04 2018-10-03 Продукты слияния транстиретина и иммуноглобулина

Country Status (12)

Country Link
US (1) US20200317795A1 (ru)
EP (1) EP3692061A1 (ru)
JP (2) JP2020537506A (ru)
KR (1) KR20200059281A (ru)
CN (1) CN111164101A (ru)
AU (1) AU2018346151A1 (ru)
CA (1) CA3076630A1 (ru)
EA (1) EA202090581A1 (ru)
MA (1) MA50619A (ru)
MX (1) MX2020003549A (ru)
SG (1) SG11202003114UA (ru)
WO (1) WO2019070901A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022540089A (ja) * 2019-07-08 2022-09-14 アムジエン・インコーポレーテツド 多特異性トランスサイレチン免疫グロブリン融合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
GB0601513D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
PL2975051T3 (pl) 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
EP3838922A1 (en) * 2010-10-27 2021-06-23 Amgen Inc. Dkk1 antibodies and methods of use
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2014144632A2 (en) * 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
EP3013860B1 (en) 2013-06-26 2018-12-12 Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
CN106977609B (zh) * 2017-04-19 2020-07-28 刘崇东 一种融合蛋白、制备方法及其应用

Also Published As

Publication number Publication date
WO2019070901A1 (en) 2019-04-11
SG11202003114UA (en) 2020-05-28
EP3692061A1 (en) 2020-08-12
CA3076630A1 (en) 2019-04-11
JP2020537506A (ja) 2020-12-24
US20200317795A1 (en) 2020-10-08
MA50619A (fr) 2020-08-12
AU2018346151A1 (en) 2020-04-02
JP2024012336A (ja) 2024-01-30
MX2020003549A (es) 2020-08-03
KR20200059281A (ko) 2020-05-28
CN111164101A (zh) 2020-05-15

Similar Documents

Publication Publication Date Title
EA201891322A1 (ru) Анти-tl1a/анти-tnf-альфа биспецифические антигенсвязывающие белки и их применение
EA201892793A1 (ru) Анти-hla-g специфические антитела
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
CR20190227A (es) Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15ra y fragmentos de anticuerpo pd-1
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
PE20190737A1 (es) Anticuerpos anti-cd27
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
WO2015184001A8 (en) Anti-tnf-alpha glycoantibodies and uses thereof
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
PH12019502298A1 (en) Monoclonal antibody to pd-l1
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
MX2020000288A (es) Cromatografia.
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
EA201890171A1 (ru) Слитые белки btla агонисты и их применение
EA202090581A1 (ru) Продукты слияния транстиретина и иммуноглобулина
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos